Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
BMND15
MCID: BNM029
MIFTS: 51

Bone Mineral Density Quantitative Trait Locus 15 (BMND15)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 15

About this section

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 15:

Name: Bone Mineral Density Quantitative Trait Locus 15 57 6 40
Osteoporosis 57 72
Metaphyseal Fracture, Susceptibility to 57
Compression Fracture, Susceptibility to 57
Osteoporosis, Susceptibility to 57
Fractures, Compression 72
Metaphyseal Fracture 57
Compression Fracture 57
Bmnd15 57

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive
autosomal dominant


HPO:

32
bone mineral density quantitative trait locus 15:
Inheritance autosomal dominant inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Fetal diseases Rare diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 57 613418
MedGen 42 C3150680
UMLS 72 C0029456 C0521169
Sources

Summaries for Bone Mineral Density Quantitative Trait Locus 15

About this section
MalaCards based summary : Bone Mineral Density Quantitative Trait Locus 15, also known as osteoporosis, is related to osteoporosis and osteoporosis, juvenile, and has symptoms including tremor, angina pectoris and back pain. An important gene associated with Bone Mineral Density Quantitative Trait Locus 15 is MIR2861 (MicroRNA 2861), and among its related pathways/superpathways are Regulation of TP53 Activity and Transcriptional activity of SMAD2/SMAD3-SMAD4 heterotrimer. The drugs Linagliptin and Magnesium oxide have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate, and related phenotype is osteoporosis.

More information from OMIM: 613418
Sources

Related Diseases for Bone Mineral Density Quantitative Trait Locus 15

About this section

Diseases in the Bone Mineral Density Quantitative Trait Locus 15 family:

Bone Mineral Density Quantitative Trait Locus 4 Bone Mineral Density Quantitative Trait Locus 18
Bone Mineral Density Quantitative Trait Locus 1 Bone Mineral Density Quantitative Trait Locus 2
Bone Mineral Density Quantitative Trait Locus 3 Bone Mineral Density Quantitative Trait Locus 5
Bone Mineral Density Quantitative Trait Locus 6 Bone Mineral Density Quantitative Trait Locus 7
Bone Mineral Density Quantitative Trait Locus 8 Bone Mineral Density Quantitative Trait Locus 9
Bone Mineral Density Quantitative Trait Locus 10 Bone Mineral Density Quantitative Trait Locus 11
Bone Mineral Density Quantitative Trait Locus 12 Bone Mineral Density Quantitative Trait Locus 13
Bone Mineral Density Quantitative Trait Locus 14 Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 15 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1083)
# Related Disease Score Top Affiliating Genes
1 osteoporosis 33.3 PDLIM4 MIR2861 CALCR
2 osteoporosis, juvenile 12.9
3 osteoporosis-pseudoglioma syndrome 12.8
4 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.6
5 glucocorticoid-induced osteoporosis 12.6
6 juvenile primary osteoporosis 12.6
7 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.5
8 osteoporosis and oculocutaneous hypopigmentation syndrome 12.5
9 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 12.3
10 growth failure, microcephaly, mental retardation, cataracts, large joint contractures, osteoporosis, cortical dysplasia, and cerebellar atrophy 12.2
11 dominant hypophosphatemia with nephrolithiasis or osteoporosis 12.2
12 bone mineral density quantitative trait locus 8 12.2
13 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 12.2
14 hajdu-cheney syndrome 12.1
15 cutis laxa osteoporosis 12.1
16 osteoporosis-macrocephaly-blindness-joint hyperlaxity syndrome 12.1
17 lrp5-related primary osteoporosis 12.1
18 bone mineral density quantitative trait locus 18 12.0
19 acroosteolysis dominant type 12.0
20 bone mineral density quantitative trait locus 16 11.8
21 premature ovarian failure 1 11.6
22 aromatase deficiency 11.6
23 bone mineral density quantitative trait locus 12 11.6
24 bone disease 11.6
25 werner syndrome 11.6
26 syndromic x-linked intellectual disability snyder type 11.6
27 lysinuric protein intolerance 11.5
28 mental retardation, x-linked, syndromic, snyder-robinson type 11.5
29 geroderma osteodysplasticum 11.5
30 hyperparathyroidism 11.5
31 rickets 11.5
32 premature aging syndrome, okamoto type 11.4
33 cerebrotendinous xanthomatosis 11.4
34 acth-secreting pituitary adenoma 11.4
35 cholangitis, primary sclerosing 11.4
36 spondyloocular syndrome 11.4
37 cleidocranial dysplasia 11.4
38 anorexia nervosa 11.4
39 celiac disease 1 11.4
40 systemic mastocytosis 11.4
41 spondyloepimetaphyseal dysplasia, shohat type 11.3
42 osteopetrosis 11.3
43 hypogonadotropic hypogonadism 11.3
44 graves' disease 11.3
45 severe congenital neutropenia 11.3
46 turner syndrome 11.3
47 pituitary adenoma 4, acth-secreting 11.3
48 homocystinuria 11.3
49 exudative vitreoretinopathy 11.3
50 spinal disease 11.3

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 15:



Diseases related to Bone Mineral Density Quantitative Trait Locus 15
Sources

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 15

About this section

Human phenotypes related to Bone Mineral Density Quantitative Trait Locus 15:

32
# Description HPO Frequency HPO Source Accession
1 osteoporosis 32 HP:0000939

Symptoms via clinical synopsis from OMIM:

57
Skeletal:
osteoporosis
compression fractures (in homozygotes)
metaphyseal fractures (in homozygotes)

Clinical features from OMIM:

613418

UMLS symptoms related to Bone Mineral Density Quantitative Trait Locus 15:


tremor, angina pectoris, back pain, sciatica, equilibration disorder, muscle cramp, pelvic pain
Sources

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 15

About this section

Drugs for Bone Mineral Density Quantitative Trait Locus 15 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 653)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4 668270-12-0 10096344
2
Magnesium oxide Approved Phase 4 1309-48-4 14792
3
Dinoprostone Approved Phase 4 363-24-6 5280360
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
7
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
8
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
9
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
12
Tibolone Approved, Investigational Phase 4 5630-53-5
13
Atorvastatin Approved Phase 4 134523-00-5 60823
14
Etanercept Approved, Investigational Phase 4 185243-69-0
15
Pamidronate Approved Phase 4 40391-99-9 4674
16
Montelukast Approved Phase 4 158966-92-8 5281040
17
Adalimumab Approved Phase 4 331731-18-1 16219006
18
Norethindrone Approved Phase 4 68-22-4 6230
19
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
20
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
21
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
22
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
23
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
24
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
25
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
26
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
27
Gliclazide Approved Phase 4 21187-98-4 3475
28
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
29
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
30
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
31
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
32
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
33
Ribavirin Approved Phase 4 36791-04-5 37542
34
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
35
Liraglutide Approved Phase 4 204656-20-2 44147092
36
Azathioprine Approved Phase 4 446-86-6 2265
37
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
38
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
39
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
40
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
41
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
42
Morphine Approved, Investigational Phase 4 57-27-2 5288826
43
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
44
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
45
Radium Ra 223 dichloride Approved, Investigational Phase 4 444811-40-9
46
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
47
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
48
Sodium citrate Approved, Investigational Phase 4 68-04-2
49
Cinacalcet Approved Phase 4 226256-56-0 156419
50
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051

Interventional clinical trials:

(show top 50) (show all 2072)
# Name Status NCT ID Phase Drugs
1 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
2 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
3 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
4 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
5 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
6 Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
7 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
8 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
9 A Comparative Study of Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty in Patients With Osteoporotic Femoral Neck Fractures Unknown status NCT02148848 Phase 4 Risedronate
10 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
11 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
12 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
13 The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion Unknown status NCT01310465 Phase 4 zoledronic acid;sodium chloride
14 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
15 Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease Unknown status NCT02792413 Phase 4 Denosumab;NaCl (placebo)
16 Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
17 Open Labeled, Propective, Multicentric Phase IV Study to Examine the Influence of Pharmacogenetic Markers on the Efficacy and Side Effects in Postmenopausal, Steroid Hormone Positive Breast Cancer Patients, Who Are Treated With Letrozol. Unknown status NCT01908556 Phase 4 Letrozole
18 A Feasibility Study to Explore the Difference in Healing Time Between Teriparatide Treatment and Standard Care on Weber B Ankle Fractures in Older People Unknown status NCT02955056 Phase 4 Forsteo
19 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
20 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
21 A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
22 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
23 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
24 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
25 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
26 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
27 Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures Completed NCT01383616 Phase 4
28 Study of Curette Use for Obtaining Restoration of Vertebral Body Anatomy in Balloon Kyphoplasty Completed NCT00810043 Phase 4
29 Study to Evaluate the Clinical Performance of the VBS System for the Treatment of Osteoporotic Vertebral Fractures in a Multicenter, Randomized, Controlled Setting Completed NCT01847898 Phase 4
30 Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene Completed NCT00079924 Phase 4 teriparatide;aldrenodate;raloxifene
31 Prospective Randomized Study of Balloon Kyphoplasty and Vertebroplasty in Subacute (Older Than 6 Weeks) Osteoporotic Vertebral Fractures (STIC2) Completed NCT00749086 Phase 4
32 Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
33 Teriparatide Compared With Alendronate on Spine Bone Mineral Density in Postmenopausal Women With Osteoporosis Completed NCT02416271 Phase 4 Teriparatide;Alendronate;Placebo-Oral;Placebo-SC
34 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
35 Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis Completed NCT00239629 Phase 4 Teriparatide;Strontium ranelate
36 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
37 Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis Completed NCT01544894 Phase 4 Raloxifene;Strontium ranelate
38 A One Year, Parallel, Placebo-controlled, Double-blind, Randomized Study to Assess the Effect of Monthly 150mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis Completed NCT02948881 Phase 4 ibandronate
39 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg Completed NCT00549965 Phase 4 Risedronate Sodium
40 Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis Completed NCT00532545 Phase 4 Teriparatide
41 EVA: Evista Alendronate Comparison Completed NCT00035971 Phase 4 raloxifene HCI and alendronate Na
42 A Study of Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene HCl or Placebo Completed NCT00532246 Phase 4 raloxifene;Placebo
43 Open Label, Multi-centre, Longitudinal, Prospective, Phase IV Clinical Trial to Compare Two Image Technologies (ImaTx and DXA) Assessing the Anabolic Effects of PTH(1-84) in Postmenopausal Women With Primary Osteoporosis Completed NCT00583518 Phase 4 Parathyroid hormone (PTH)
44 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
45 A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients Completed NCT02598934 Phase 4 Ibandronate
46 A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study Completed NCT02598440 Phase 4 Alendronate;Ibandronate
47 Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study Completed NCT00548509 Phase 4 Menatetrenone (Vitamin K2)
48 An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
49 An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)
50 A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women Completed NCT00729651 Phase 4 alendronate sodium (+) cholecalciferol;Comparator: Alendronate sodium (Fosamax)

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 15

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cholecalciferol
Fluorides
Medium chain triglycerides
MEDRONATE DISODIUM
SODIUM FLUORIDE PWDR
Sources

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 15

About this section
Sources

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 15

About this section

MalaCards organs/tissues related to Bone Mineral Density Quantitative Trait Locus 15:

41
Bone, Breast, Prostate, Testes, Kidney, Bone Marrow, Liver
Sources

Publications for Bone Mineral Density Quantitative Trait Locus 15

About this section

Articles related to Bone Mineral Density Quantitative Trait Locus 15:

(show top 50) (show all 30003)
# Title Authors PMID Year
1
A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. 38 8 71
19920351 2009
2
Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. 38 71
9817931 1998
3
Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. 71
12908099 2003
4
Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian women. 71
9571205 1998
5
Allelic variants of human calcitonin receptor in the Japanese population. 71
9003491 1997
6
The therapeutic effect of secretome from human umbilical cord-derived mesenchymal stem cells in age-related osteoporosis. 38
30977425 2019
7
Racial differences in skeletal fragility but not osteoarthritis among women and men with cerebral palsy. 38
31417943 2019
8
An insight into the paradigms of osteoporosis: From genetics to biomechanics. 38
31372373 2019
9
Experiences of striving to maintain daily life among women with osteoporosis. 38
31349764 2019
10
Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. 38
30665323 2019
11
Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility. 38
30909788 2019
12
Conservative treatment of recurrent symptoms of an incomplete, atypical femoral fracture associated with glucocorticoid, bisphosphonate, and denosumab therapy in a patient with chronic obstructive pulmonary disease. 38
30336748 2019
13
Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways. 38
31323222 2019
14
Integrated pathological cell fishing and network pharmacology approach to investigate main active components of Er-Xian decotion for treating osteoporosis. 38
31136804 2019
15
Insight into the possible role of miR-214 in primary osteoporosis via osterix. 38
31056782 2019
16
Comprehensive circular RNA profiling reveals circ_0002060 as a potential diagnostic biomarkers for osteoporosis. 38
31056800 2019
17
Calcium Metabolic Disorders in Pregnancy: Primary Hyperparathyroidism, Pregnancy-Induced Osteoporosis, and Vitamin D Deficiency in Pregnancy. 38
31345528 2019
18
circRNA_0006393 promotes osteogenesis in glucocorticoid‑induced osteoporosis by sponging miR‑145‑5p and upregulating FOXO1. 38
31322188 2019
19
An update on therapies for the treatment of diabetes-induced osteoporosis. 38
31079501 2019
20
Pulsed vibro-acoustic method for assessment of osteoporosis & osteopenia: A feasibility study on human subjects. 38
31125891 2019
21
Muscle-bone crosstalk and potential therapies for sarco-osteoporosis. 38
31106446 2019
22
Chocolate and chocolate constituents influence bone health and osteoporosis risk. 38
31029926 2019
23
Predictors of Nephrolithiasis, Osteoporosis, and Mortality in Primary Hyperparathyroidism. 38
30916764 2019
24
The genetic architecture of osteoporosis and fracture risk. 38
30980960 2019
25
Fracture prediction, imaging and screening in osteoporosis. 38
31189982 2019
26
Mendelian bone fragility disorders. 38
31039433 2019
27
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. 38
30748011 2019
28
A novel quantitative method for estimating bone mineral density using B-mode ultrasound and radiofrequency signals-a pilot study on patients with rheumatoid arthritis. 38
31410123 2019
29
Letter to the Editor: "Two-Thirds of All Fractures Are Not Attributable to Osteoporosis and Advancing Age: Implication for Fracture Prevention". 38
31116397 2019
30
Response to Letter to the Editor: "Two-Thirds of All Fractures Are Not Attributable to Osteoporosis and Advancing Age: Implication for Fracture Prevention". 38
31116398 2019
31
Mendelian randomization in the bone field. 38
30321669 2019
32
Assessment of finite element models for prediction of osteoporotic fracture. 38
31151004 2019
33
SP1-stimulated miR-545-3p inhibits osteogenesis via targeting LRP5-activated Wnt/beta-catenin signaling. 38
31327495 2019
34
Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. 38
30955181 2019
35
Eldecalcitol, an active vitamin D analog, effectively prevents cyclophosphamide-induced osteoporosis in rats. 38
31410111 2019
36
Strong Bones, Strong Body. 38
31378294 2019
37
The use of CT Hounsfield unit values to identify the undiagnosed spinal osteoporosis in patients with lumbar degenerative diseases. 38
30306332 2019
38
Wnt3a involved in the mechanical loading on improvement of bone remodeling and angiogenesis in a postmenopausal osteoporosis mouse model. 38
31017804 2019
39
MicroRNA-449b-5p promotes the progression of osteoporosis by inhibiting osteogenic differentiation of BMSCs via targeting Satb2. 38
31378877 2019
40
Ginkgolide B promotes osteoblast differentiation via activation of canonical Wnt signalling and alleviates osteoporosis through a bone anabolic way. 38
31225702 2019
41
Long-Term Effects of Teriparatide Followed by Antiresorptive Therapy on Clinical Outcomes in Patients with Severe Spinal Osteoporosis. 38
31115640 2019
42
Cav 1.2 regulates osteogenesis of bone marrow-derived mesenchymal stem cells via canonical Wnt pathway in age-related osteoporosis. 38
31120193 2019
43
Silencing of LncRNA-ANCR Promotes the Osteogenesis of Osteoblast Cells in Postmenopausal Osteoporosis via Targeting EZH2 and RUNX2. 38
31347330 2019
44
Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study. 38
31392401 2019
45
Hyaluronic acid modified risedronate and teriparatide co-loaded nanocarriers for improved osteogenic differentiation of osteoblasts for treatment of osteoporosis. 38
31368869 2019
46
Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China). 38
31021904 2019
47
Acupoint injection treatment for primary osteoporosis: A systematic review and meta-analysis of randomized controlled trials protocol. 38
31393383 2019
48
Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis. 38
31343176 2019
49
Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis : Comment on "Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis". 38
31143992 2019
50
MiRNA-19a-3p alleviates the progression of osteoporosis by targeting HDAC4 to promote the osteogenic differentiation of hMSCs. 38
31248594 2019
Sources

Variations for Bone Mineral Density Quantitative Trait Locus 15

About this section

ClinVar genetic disease variations for Bone Mineral Density Quantitative Trait Locus 15:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MIR2861 NR_036055.1(MIR2861): n.33C> G single nucleotide variant association rs794728003 9:130548229-130548229 9:127785950-127785950
2 PDLIM4 RIL, -3333T-C single nucleotide variant risk factor
3 CALCR NM_001742.4(CALCR): c.1340T> C (p.Leu447Pro) single nucleotide variant risk factor rs1801197 7:93055753-93055753 7:93426441-93426441
Sources

Expression for Bone Mineral Density Quantitative Trait Locus 15

About this section
Search GEO for disease gene expression data for Bone Mineral Density Quantitative Trait Locus 15.
Sources

Pathways for Bone Mineral Density Quantitative Trait Locus 15

About this section

Pathways related to Bone Mineral Density Quantitative Trait Locus 15 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Regulation of TP53 Activity 66
Show member pathways
 12.32 MIR3960 MIR2861 CDK9
2
Transcriptional activity of SMAD2/SMAD3-SMAD4 heterotrimer 66
Show member pathways
 11.74 MIR3960 MIR2861 CDK9
3
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 11.53 MIR3960 MIR2861 CDK9
4
IL-7 Signaling Pathway 1
Show member pathways
 10.79 MIR3960 MIR2861 CDK9
5
Initiation of transcription and translation elongation at the HIV-1 LTR 1
10.37 MIR3960 MIR2861 CDK9
Sources

GO Terms for Bone Mineral Density Quantitative Trait Locus 15

About this section
Sources

Sources for Bone Mineral Density Quantitative Trait Locus 15

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....